Annual Total Liabilities
$4.00 M
-$3.48 M-46.53%
December 31, 2023
Summary
- As of February 7, 2025, RSLS annual total liabilities is $4.00 million, with the most recent change of -$3.48 million (-46.53%) on December 31, 2023.
- During the last 3 years, RSLS annual total liabilities has fallen by -$18.57 million (-82.28%).
- RSLS annual total liabilities is now -82.28% below its all-time high of $22.57 million, reached on December 31, 2020.
Performance
RSLS Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$4.13 M
+$770.00 K+22.93%
September 30, 2024
Summary
- As of February 7, 2025, RSLS quarterly total liabilities is $4.13 million, with the most recent change of +$770.00 thousand (+22.93%) on September 30, 2024.
- Over the past year, RSLS quarterly total liabilities has dropped by -$616.00 thousand (-12.98%).
- RSLS quarterly total liabilities is now -93.33% below its all-time high of $61.88 million, reached on June 30, 2021.
Performance
RSLS Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
RSLS Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -46.5% | -13.0% |
| 3 y3 years | -82.3% | -64.0% |
| 5 y5 years | -72.6% | -78.8% |
RSLS Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -51.2% | at low | -56.8% | +22.9% |
| 5 y | 5-year | -82.3% | at low | -93.3% | +22.9% |
| alltime | all time | -82.3% | +188.4% | -93.3% | +22.9% |
ReShape Lifesciences Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $4.13 M(+22.9%) |
| Jun 2024 | - | $3.36 M(-9.2%) |
| Mar 2024 | - | $3.70 M(-7.6%) |
| Dec 2023 | $4.00 M(-46.5%) | $4.00 M(-15.7%) |
| Sep 2023 | - | $4.74 M(-7.2%) |
| Jun 2023 | - | $5.11 M(-40.5%) |
| Mar 2023 | - | $8.59 M(+14.9%) |
| Dec 2022 | $7.48 M(-8.7%) | $7.48 M(-0.4%) |
| Sep 2022 | - | $7.51 M(-21.4%) |
| Jun 2022 | - | $9.56 M(+10.6%) |
| Mar 2022 | - | $8.64 M(+5.5%) |
| Dec 2021 | $8.20 M(-63.7%) | $8.20 M(-28.6%) |
| Sep 2021 | - | $11.48 M(-81.5%) |
| Jun 2021 | - | $61.88 M(+165.5%) |
| Mar 2021 | - | $23.31 M(+3.3%) |
| Dec 2020 | $22.57 M(+45.2%) | $22.57 M(+15.7%) |
| Sep 2020 | - | $19.51 M(+8.4%) |
| Jun 2020 | - | $17.99 M(+12.5%) |
| Mar 2020 | - | $15.99 M(+2.8%) |
| Dec 2019 | $15.55 M(+6.4%) | $15.55 M(-74.0%) |
| Sep 2019 | - | $59.84 M(+97.5%) |
| Jun 2019 | - | $30.30 M(+60.7%) |
| Mar 2019 | - | $18.85 M(+29.0%) |
| Dec 2018 | $14.61 M(+18.4%) | $14.61 M(+32.8%) |
| Sep 2018 | - | $11.01 M(-3.5%) |
| Jun 2018 | - | $11.40 M(-10.2%) |
| Mar 2018 | - | $12.69 M(+2.9%) |
| Dec 2017 | $12.34 M(+200.8%) | $12.34 M(+198.3%) |
| Sep 2017 | - | $4.14 M(-8.4%) |
| Jun 2017 | - | $4.51 M(+19.9%) |
| Mar 2017 | - | $3.76 M(-8.2%) |
| Dec 2016 | $4.10 M(-48.2%) | $4.10 M(-56.5%) |
| Sep 2016 | - | $9.42 M(-49.3%) |
| Jun 2016 | - | $18.60 M(+15.4%) |
| Mar 2016 | - | $16.11 M(+103.6%) |
| Dec 2015 | $7.91 M | $7.91 M(+8.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2015 | - | $7.27 M(+12.6%) |
| Jun 2015 | - | $6.45 M(-8.1%) |
| Mar 2015 | - | $7.02 M(-9.1%) |
| Dec 2014 | $7.72 M(-34.1%) | $7.72 M(-8.3%) |
| Sep 2014 | - | $8.42 M(-13.5%) |
| Jun 2014 | - | $9.74 M(-5.7%) |
| Mar 2014 | - | $10.32 M(-11.8%) |
| Dec 2013 | $11.71 M(-17.7%) | $11.71 M(-4.5%) |
| Sep 2013 | - | $12.26 M(-6.0%) |
| Jun 2013 | - | $13.04 M(-10.2%) |
| Mar 2013 | - | $14.52 M(+2.1%) |
| Dec 2012 | $14.22 M(+14.3%) | $14.22 M(+2.2%) |
| Sep 2012 | - | $13.91 M(+4.3%) |
| Jun 2012 | - | $13.33 M(+41.5%) |
| Mar 2012 | - | $9.42 M(-24.3%) |
| Dec 2011 | $12.45 M(+38.6%) | $12.45 M(+27.9%) |
| Sep 2011 | - | $9.73 M(+12.6%) |
| Jun 2011 | - | $8.64 M(+2.4%) |
| Mar 2011 | - | $8.44 M(-6.0%) |
| Dec 2010 | $8.98 M(-15.5%) | $8.98 M(-0.6%) |
| Sep 2010 | - | $9.04 M(+1.9%) |
| Jun 2010 | - | $8.87 M(-11.8%) |
| Mar 2010 | - | $10.06 M(-5.4%) |
| Dec 2009 | $10.63 M(-37.0%) | $10.63 M(-57.9%) |
| Sep 2009 | - | $25.28 M(-7.5%) |
| Jun 2009 | - | $27.32 M(+49.5%) |
| Mar 2009 | - | $18.27 M(+8.3%) |
| Dec 2008 | $16.87 M(+22.5%) | $16.87 M(+28.3%) |
| Sep 2008 | - | $13.16 M(-3.2%) |
| Jun 2008 | - | $13.60 M(+7.1%) |
| Mar 2008 | - | $12.70 M(-7.8%) |
| Dec 2007 | $13.77 M(+83.8%) | $13.77 M(+18.1%) |
| Sep 2007 | - | $11.66 M(+55.6%) |
| Dec 2006 | $7.49 M(-21.9%) | $7.49 M(-21.9%) |
| Dec 2005 | $9.59 M(+591.2%) | $9.59 M |
| Dec 2003 | $1.39 M | - |
FAQ
- What is ReShape Lifesciences annual total liabilities?
- What is the all time high annual total liabilities for ReShape Lifesciences?
- What is ReShape Lifesciences annual total liabilities year-on-year change?
- What is ReShape Lifesciences quarterly total liabilities?
- What is the all time high quarterly total liabilities for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly total liabilities year-on-year change?
What is ReShape Lifesciences annual total liabilities?
The current annual total liabilities of RSLS is $4.00 M
What is the all time high annual total liabilities for ReShape Lifesciences?
ReShape Lifesciences all-time high annual total liabilities is $22.57 M
What is ReShape Lifesciences annual total liabilities year-on-year change?
Over the past year, RSLS annual total liabilities has changed by -$3.48 M (-46.53%)
What is ReShape Lifesciences quarterly total liabilities?
The current quarterly total liabilities of RSLS is $4.13 M
What is the all time high quarterly total liabilities for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly total liabilities is $61.88 M
What is ReShape Lifesciences quarterly total liabilities year-on-year change?
Over the past year, RSLS quarterly total liabilities has changed by -$616.00 K (-12.98%)